2月3日，悦康药业跌0.59%，截至发稿，报21.93元/股，成交2.77亿元，换手率2.86%，总市值98.69亿 元。悦康药业股价已经连续7天下跌，区间累计跌幅19.23%。 资料显示，悦康药业集团股份有限公司位于北京市北京经济技术开发区宏达中路6号,香港铜锣湾希慎道 33号利园1期19楼1919室，成立日期2001年8月14日，上市日期2020年12月24日，公司主营业务涉及悦康 药业定位于高端化学药的研发与生产,报告期内主营业务收入主要集中在心脑血管药物、消化系统药 物、糖尿病用药以及抗感染药物等。银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑 肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未 来增长潜力较大,是公司的主要产品。主营业务收入构成为：心脑血管类55.67%，抗感染20.88%，原料 药8.73%，消化系统类6.87%，降糖类4.85%，其他2.62%，其他(补充)0.36%，技术服务0.02%。 责任编辑：小浪快报 数据显示，华富基金旗下1只基金重仓悦康药业。华富健康文娱灵活配置混合A（001563）四季度持有 股数52万股，占基金净 ...

2月2日，悦康药业跌5.15%，截至发稿，报23.01元/股，成交9003.05万元，换手率0.85%，总市值103.55 亿元。悦康药业股价已经连续5天下跌，区间累计跌幅10.64%。 资料显示，悦康药业集团股份有限公司位于北京市北京经济技术开发区宏达中路6号,香港铜锣湾希慎道 33号利园1期19楼1919室，成立日期2001年8月14日，上市日期2020年12月24日，公司主营业务涉及悦康 药业定位于高端化学药的研发与生产,报告期内主营业务收入主要集中在心脑血管药物、消化系统药 物、糖尿病用药以及抗感染药物等。银杏叶提取物注射液、天麻素注射液、注射用兰索拉唑、奥美拉唑 肠溶胶囊、盐酸二甲双胍缓释片、注射用头孢呋辛钠、注射用头孢曲松钠对公司收入贡献占比较大或未 来增长潜力较大,是公司的主要产品。主营业务收入构成为：心脑血管类55.67%，抗感染20.88%，原料 药8.73%，消化系统类6.87%，降糖类4.85%，其他2.62%，其他(补充)0.36%，技术服务0.02%。 从悦康药业十大流通股东角度 易方达医疗保健行业混合A（110023）基金经理为杨桢霄。 截至发稿，杨桢霄累计任职时间9年169天，现 ...

Group 1 - The core point of the news is that Yuyuan Pharmaceutical experienced a decline of 5.21% in its stock price, reaching 27.10 yuan per share, with a total market capitalization of 12.195 billion yuan [1] - Yuyuan Pharmaceutical, established on August 14, 2001, and listed on December 24, 2020, focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [1] - The main products contributing to the company's revenue include Ginkgo biloba extract injection, Tianma extract injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection, indicating strong future growth potential [1] Group 2 - According to data, Guangfa Fund holds a significant position in Yuyuan Pharmaceutical, with its Guangfa Balanced Return Mixed A Fund holding 609,700 shares, unchanged from the previous period, representing 2.19% of the fund's net value [2] - The Guangfa Balanced Return Mixed A Fund, established on June 23, 2021, has a current scale of 612 million yuan, with a year-to-date return of 3.48% and a one-year return of 17.78% [2]

Group 1 - The core viewpoint of the news is that Yuyuan Pharmaceutical has seen a significant increase in stock price and trading volume, indicating positive market sentiment towards the company [1] - As of January 9, Yuyuan Pharmaceutical's stock price rose by 5.2% to 28.55 CNY per share, with a trading volume of 204 million CNY and a turnover rate of 1.65%, resulting in a total market capitalization of 12.847 billion CNY [1] - The company, established in August 2001 and listed in December 2020, focuses on the research and production of high-end chemical drugs, with major revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [1] Group 2 - Yuyuan Pharmaceutical's main products include Ginkgo biloba extract injection, Tianma extract injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection, which are expected to have significant revenue contributions and growth potential [1] - The revenue composition of Yuyuan Pharmaceutical is as follows: cardiovascular drugs 55.67%, anti-infection drugs 20.88%, raw materials 8.73%, digestive system drugs 6.87%, diabetes drugs 4.85%, and others 2.62% [1] Group 3 - Red Tower Hongtu Fund has a significant holding in Yuyuan Pharmaceutical, with its Red Tower Hongtu Medical Selected Stock Fund A (020331) holding 23,000 shares, accounting for 3.82% of the fund's net value, ranking as the tenth largest holding [2] - The fund has achieved a year-to-date return of 3.15%, ranking 2758 out of 5509 in its category, and a one-year return of 37.37%, ranking 2023 out of 4198 [2]

Group 1 - The core viewpoint of the news is that Yuyuan Pharmaceutical has shown a significant increase in stock price and has a strong market presence in high-end chemical drug development and production [1] - As of January 6, Yuyuan Pharmaceutical's stock rose by 5.46%, reaching 26.26 yuan per share, with a total market capitalization of 11.817 billion yuan [1] - The company's main business revenue is concentrated in cardiovascular drugs (55.67%), anti-infection drugs (20.88%), raw materials (8.73%), digestive system drugs (6.87%), diabetes medications (4.85%), and others [1] Group 2 - Huashan Fund holds a significant position in Yuyuan Pharmaceutical, with the Huashan CSI 1000 Index Enhanced A Fund being the ninth largest holding, comprising 0.4% of the fund's net value [2] - The fund has a total scale of 45.938 million yuan and has achieved a year-to-date return of 2.14% [2] - The fund manager, Zhang Xu, has a tenure of 5 years and 235 days, with the best fund return during this period being 145.19% [3]

Core Viewpoint - Yuyuan Pharmaceutical experienced a stock price decline of 2.08% on December 18, with a current price of 21.68 CNY per share and a market capitalization of 9.756 billion CNY [1] Financial Performance - For the period from January to September 2025, Yuyuan Pharmaceutical reported a revenue of 1.759 billion CNY, a year-on-year decrease of 41.20%, and a net profit attributable to shareholders of -148 million CNY, a year-on-year decrease of 170.56% [3] - The company has distributed a total of 1.092 billion CNY in dividends since its A-share listing, with 584 million CNY distributed over the past three years [4] Stock Market Activity - Yuyuan Pharmaceutical's stock has increased by 50.45% year-to-date, but has seen a decline of 19.23% over the last five trading days, 3.08% over the last 20 days, and 11.98% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on August 27, where it recorded a net buy of -105 million CNY [1] Shareholder Information - As of September 30, 2025, Yuyuan Pharmaceutical had 10,700 shareholders, a decrease of 8.39% from the previous period, with an average of 42,095 circulating shares per shareholder, an increase of 9.16% [3] - The top ten circulating shareholders include notable funds such as the Fortune Precision Medical Flexible Allocation Mixed A and the E Fund Healthcare Industry Mixed A, with changes in their holdings noted [4] Business Overview - Yuyuan Pharmaceutical, established on August 14, 2001, and listed on December 24, 2020, focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [2] - The revenue composition includes 55.67% from cardiovascular drugs, 20.88% from anti-infection drugs, and smaller percentages from other categories [2]

Group 1 - The core viewpoint of the news is that Yuyuan Pharmaceutical has seen a significant increase in its stock price, with a rise of 5.34% to 21.89 yuan per share, and a total market capitalization of 9.85 billion yuan [1] - Yuyuan Pharmaceutical, established on August 14, 2001, and listed on December 24, 2020, focuses on the research and production of high-end chemical drugs, with major revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [1] - The main products contributing to the company's revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection, indicating strong growth potential [1] Group 2 - From the perspective of fund holdings, Yuyuan Pharmaceutical is a significant position in the Huashan Fund, specifically in the Huashan CSI 1000 Index Enhanced A fund, which held 10,500 shares, accounting for 0.4% of the fund's net value [2] - The Huashan CSI 1000 Index Enhanced A fund has a total scale of 45.938 million yuan and has achieved a year-to-date return of 24.74%, ranking 2011 out of 4208 in its category [2] - The fund manager, Zhang Xu, has a tenure of 5 years and 188 days, with the best fund return during this period being 142.52% [3]

Group 1 - The core viewpoint of the news is that Yuyuan Pharmaceutical has seen a 5% increase in stock price, reaching 21.62 CNY per share, with a total market capitalization of 9.729 billion CNY [1] - Yuyuan Pharmaceutical focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular drugs, digestive system drugs, diabetes medications, and anti-infection drugs [1] - The main products contributing to the company's revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection [1] Group 2 - Huashan Fund has a significant holding in Yuyuan Pharmaceutical, with the Huashan CSI 1000 Index Enhanced A fund holding 10,500 shares, representing 0.4% of the fund's net value [2] - The Huashan CSI 1000 Index Enhanced A fund has achieved a year-to-date return of 25.63% and a one-year return of 28.95% [2] - The fund manager, Zhang Xu, has a tenure of 5 years and 168 days, with the best fund return during this period being 144.8% [3]

Core Viewpoint - Yuyuan Pharmaceutical experienced a 5.01% decline in stock price, closing at 22.58 yuan per share, with a trading volume of 156 million yuan and a turnover rate of 1.50%, resulting in a total market capitalization of 10.161 billion yuan [1] Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. is located in Beijing Economic and Technological Development Zone and was established on August 14, 2001, with its listing date on December 24, 2020 [1] - The company focuses on the research and production of high-end chemical drugs, with major revenue contributions from cardiovascular drugs, digestive system drugs, diabetes medications, and anti-infection drugs [1] - Key products contributing significantly to revenue include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection [1] - The revenue composition is as follows: cardiovascular drugs 55.67%, anti-infection 20.88%, raw materials 8.73%, digestive system 6.87%, diabetes 4.85%, others 2.62%, and technical services 0.02% [1] Shareholder Information - Southern Fund's Southern Medical Health Flexible Allocation Mixed A Fund (000452) is among the top ten circulating shareholders of Yuyuan Pharmaceutical, holding 7.2677 million shares, unchanged from the previous period, representing 1.62% of circulating shares [2] - The fund has incurred an estimated floating loss of approximately 8.6486 million yuan [2] - The fund was established on January 23, 2014, with a latest scale of 2.405 billion yuan, achieving a year-to-date return of 51.3% and a one-year return of 57.73% [2] Fund Management - The fund manager of Southern Medical Health Flexible Allocation Mixed A is Wang Zhengjiao, who has been in the position for 7 years and 63 days [3] - The total asset scale of the fund is 2.417 billion yuan, with the best return during the tenure being 75.78% and the worst return being -53.83% [3] Fund Holdings - Southern Medical Health Flexible Allocation Mixed A Fund has Yuyuan Pharmaceutical as its third-largest heavy stock, holding 7.2677 million shares, unchanged from the previous period, representing 5.72% of the fund's net value [4] - The fund has also experienced a floating loss of approximately 8.6486 million yuan [4]

Core Viewpoint - Yuyuan Pharmaceutical experienced a 5.08% increase in stock price, reaching 25.88 CNY per share, with a total market capitalization of 11.646 billion CNY as of September 18 [1] Group 1: Company Overview - Yuyuan Pharmaceutical Group Co., Ltd. was established on August 14, 2001, and went public on December 24, 2020 [1] - The company focuses on the research and production of high-end chemical drugs, with significant revenue contributions from cardiovascular, digestive, diabetes, and anti-infection medications [1] - Major products include Ginkgo biloba extract injection, Tianma injection, Lansoprazole injection, Omeprazole enteric-coated capsules, Metformin sustained-release tablets, Cefuroxime sodium injection, and Ceftriaxone sodium injection, which are expected to drive future growth [1] Group 2: Revenue Composition - The revenue composition of Yuyuan Pharmaceutical is as follows: - Cardiovascular drugs: 55.67% - Anti-infection drugs: 20.88% - Raw materials: 8.73% - Digestive system drugs: 6.87% - Diabetes drugs: 4.85% - Others: 2.62% - Supplementary: 0.36% - Technical services: 0.02% [1] Group 3: Shareholder Information - Yuyuan Pharmaceutical's top circulating shareholder includes a fund from E Fund Management, specifically the E Fund Healthcare Industry Mixed A (110023), which entered the top shareholders list in Q2 with 6.8551 million shares, representing 1.52% of circulating shares [2] - The fund has achieved a year-to-date return of 48.1% and a one-year return of 57.01% [2]